Cytogam (Cytomegalovirus Immune Globulin Intravenous) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Cytogam (Cytomegalovirus Immune Globulin Intravenous) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth in the historic period can be attributed to several factors, including an increase in organ transplantation procedures, evolving medical guidelines, the rising global incidence of CMV infections, regulatory approvals, and the prophylactic use of Cytogam in high-risk populations. Additionally, advancements in medical technologies and treatment protocols have contributed to its growing adoption.

Market growth during the forecast period is expected to be driven by several factors, including a growing geriatric population, greater awareness and global healthcare initiatives, advancements in transplantation procedures, and increased partnerships and collaborations between pharmaceutical companies and healthcare providers. Major trends in the forecast period include the increased adoption of Cytogam in organ transplantation, regional variability in demand based on healthcare infrastructure, continued advancements in biotechnology, the growing population of immunocompromised individuals, and the expanding global organ transplant market.

The rise in the number of transplant procedures is expected to propel the growth of the cytogam (cytomegalovirus immune globulin intravenous) market. Transplant procedures, where organs or tissues are transferred from a donor to a recipient, are increasing due to factors such as more organ donations, medical advancements, and improved treatment options. Cytogam is primarily used to prevent or treat cytomegalovirus (CMV) infections in immunocompromised patients, particularly those undergoing organ transplants. According to the Organ Procurement and Transplantation Network (OPTN), in January 2024, 46,632 organ transplants were performed in 2023, an 8.7% increase over 2022 and a 12.7% increase over 2021. This growing number of transplant procedures is driving the demand for cytogam, as it helps manage CMV infections in transplant patients.

A key trend in the cytogam (cytomegalovirus immune globulin intravenous) market is the focus on manufacturing technology transfer to enhance competitiveness. Manufacturing technology transfer involves transferring production knowledge, techniques, and processes to another company or facility to maintain the same quality and standards. For example, in May 2023, Kamada Ltd., an Israel-based biopharmaceutical company, launched the commercial sale of Cytogam in the U.S. after receiving FDA approval for a technology transfer from CSL Behring. Kamada's manufacturing facility in Beit Kama, Israel, now produces Cytogam, with plans to expand its availability to Canada later in the year.

In October 2022, Canadian Blood Services (CBS), a nonprofit organization, extended its partnership with Kamada Ltd. for an additional three years to supply Cytogam in Canada. This collaboration ensures the continued availability and sales of Cytogam in Canada, supporting the treatment of CMV infections in transplant patients.

Major players operating in the cytogam (cytomegalovirus immune globulin intravenous) market are CSL Behring.

North America was the largest region in the cytogam (cytomegalovirus immune globulin intravenous) market in 2024. The regions covered in cytogam (cytomegalovirus immune globulin intravenous) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cytogam (cytomegalovirus immune globulin intravenous) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cytogam (Cytomegalovirus Immune Globulin Intravenous) is an intravenous medication used to prevent and treat Cytomegalovirus (CMV) infections in immunocompromised patients, such as organ transplant recipients. It contains antibodies derived from human plasma, which help fight the CMV virus. It is typically administered to prevent CMV reactivation or infection and is often used in combination with antiviral therapies to reduce the risk of CMV-related complications in vulnerable patients.

The main dosage forms of cytogam are intravenous (IV) injection, where the medication is administered directly into the bloodstream through a vein. The clinical indications include prevention of CMV disease in transplant recipients, prophylaxis in solid organ transplant patients, prophylaxis in hematopoietic stem cell transplant patients, and use in pregnant women with primary CMV infection. The patient population includes adult and pediatric patients, and the distribution channels include hospital pharmacies, outpatient clinics, and specialty pharmacies.

The cytogam (cytomegalovirus immune globulin intravenous) market research report is one of a series of new reports that provides cytogam (cytomegalovirus immune globulin intravenous) market statistics, including cytogam (cytomegalovirus immune globulin intravenous) industry global market size, regional shares, competitors with a cytogam (cytomegalovirus immune globulin intravenous) market share, detailed cytogam (cytomegalovirus immune globulin intravenous) market segments, market trends and opportunities, and any further data you may need to thrive in the cytogam (cytomegalovirus immune globulin intravenous) industry. This cytogam (cytomegalovirus immune globulin intravenous) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cytogam (cytomegalovirus immune globulin intravenous) market consists of sales of Cytogam (Cytomegalovirus Immune Globulin Intravenous) 500 mg/10 mL and Cytogam (Cytomegalovirus Immune Globulin Intravenous) 1000 mg/20 mL. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.